Keyword: immuno-oncology

News

Merck & Co. Licenses Investigational Cancer Drug from LaNova

15.11.2024 -

US drugmaker Merck & Co. (MSD) has entered into a global license agreement to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific...

News

Celonic Acquires Glycotope Bio-manufacturing Facility

07.02.2018 - Swiss contract development and manufacturing organization (CDMO) Celonic has completed the acquisition of Glycotope’s bio-manufacturing facility in Heidelberg, Germany. Berlin...

News

AstraZeneca and Merck in Global Oncology Pact

01.08.2017 - AstraZeneca has entered into a global collaboration with US drugmaker Merck to develop and commercialize the former’s investigational cancer treatments Lynparza (olaparib) and...

News

BMS and Apexigen Link on Lung Cancer

21.04.2017 - US pharmaceutical companies Bristol-Myers Squibb and Apexigen are collaborating to test a combination of their respective drugs to treat patients with advanced solid tumors...

News

Tusk in UK Cancer Collaboration

16.02.2017 - The UK’s Tusk Therapeutics is joining Cancer Research Technology (CRT) and University College London (UCL) to research, develop and commercialize an antibody-based therapeutic...

Markets & Companies

After Pharma’s Patent Cliff

04.04.2016 - Analysts love looking into the future, particularly when it comes to big pharma’s prospect for growth and earnings. The industry experts of Morningstar see slowing patent losses...

News

Centauri and Horizon in Immuno-Oncology Link

04.03.2016 - UK companies Centauri Therapeutics and Horizon Discovery have formed a joint venture targeting the rapidly growing immuno-oncology market. The newly formed company Avvinity...

News

Merck Extends Pact with Weizmann Institute

17.02.2016 - Germany’s Merck KGaA has signed a new framework agreement with Israel’s Weizmann Institute of Science, extending their partnership for another three years with the option for...